Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan.
Toxins (Basel). 2021 Aug 29;13(9):605. doi: 10.3390/toxins13090605.
The differences in analgesic effects of botulinum toxin type A were compared in 28 patients with trigeminal neuralgia, 53 patients with myofascial temporomandibular disorders, and 89 patients with the jaw closing oromandibular dystonia. The patients were treated by injection of botulinum toxin type A into the masseter, temporalis, medial pterygoid, and other muscles based on the symptoms of each patient. The pain severity was evaluated using the visual analog scale, pain frequency, and pain scale of the oromandibular dystonia rating scale. Botulinum toxin injection was performed 1068 times in all patients without significant adverse effects. The visual analog, pain frequency, and pain scales at baseline were reduced ( < 0.001) after two, four, eight, and 12 weeks after the first botulinum toxin therapy and at the endpoint. The effects differed significantly ( < 0.001) among the groups (repeated-measures analysis of variance). The mean improvement (0%, no effect; 100%, complete recovery) at the endpoint was 86.8% for trigeminal neuralgia, 80.8% for myofascial pain, and 75.4% for oromandibular dystonia. Injection of the botulinum toxin can be a highly effective and safe method to treat trigeminal neuralgia, myofascial pain, and oromandibular dystonia.
我们比较了 A 型肉毒毒素在 28 例三叉神经痛患者、53 例肌筋膜颞下颌关节紊乱病患者和 89 例下颌闭合性口颌肌张力障碍患者中的镇痛效果。根据每位患者的症状，将肉毒毒素 A 注射到咬肌、颞肌、翼内肌和其他肌肉中。采用视觉模拟评分法、疼痛频率和口颌肌张力障碍评定量表评估疼痛严重程度。所有患者共接受 1068 次肉毒毒素注射，无明显不良反应。首次肉毒毒素治疗后 2、4、8 和 12 周及终点时，视觉模拟评分、疼痛频率和疼痛评分均降低（<0.001）。组间差异有统计学意义（重复测量方差分析）。终点时，三叉神经痛、肌筋膜痛和口颌肌张力障碍的平均改善率（0%，无效应；100%，完全缓解）分别为 86.8%、80.8%和 75.4%。肉毒毒素注射是治疗三叉神经痛、肌筋膜痛和口颌肌张力障碍的一种有效且安全的方法。
